Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Hereditary angioedema

New Real-World Data on Long-Term Prophylaxis

    • Congress Reports
    • Dermatology and venereology
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Genetics
    • RX
    • Studies
  • 3 minute read

Hereditary angioedema (HAE) is a rare genetic disorder that causes recurrent swelling of the skin, mucous membranes, or various internal organs at irregular intervals. International guidelines recommend long-term prophylaxis with lanadelumab or berotralstat as first-line therapy. The INTEGRATED trial evaluated the efficacy of lanadelumab and the effects of extending the dose interval in a real-world setting.

In the etiology of hereditary angioedema (HAE), the kallikrein-kinin system and the end product of this metabolic pathway, bradykinin, play a central role. The effects of lanadelumab – a fully humanized monoclonal antibody – are based on binding to plasma kallikrein, thereby reducing the formation of bradykinin. In Switzerland and other European countries, lanadelumab (Takhzyro®) is approved for the prophylaxis of recurrent attacks of HAE in patients over 12 years of age. The recommended starting dose is 300 mg every two weeks (q2w). “If patients are seizure-free, the administration interval can be extended to four weeksa,” explained Prof. Markus Magerl, MD, Allergie-Centrum-Charité-Universitätsmedizin Berlin. In addition, the INTEGRATED study demonstrated that individualized extension to other of the dose intervals also works (Fig. 1).

a Dose interval 4 weeks=q4w

Adjustment of the dose interval of lanadelumab during the course of the study.

The study included 198b patients over 12 years of age with HAE type I or II who had started long-term prophylaxis (LTP) with lanadelumab from November 2017 to October 2021. Of these, 182 (91.9%) had HAE type I and 16 (8.1%) had HAE type II. The mean age was 43.4 years, 61.6% were female, and 30.8% had a history of life-threatening attacks. The mean number of seizures at baseline was 35.8 over a 12-month period. The median treatment duration with lanadelumab was 28.8 months (interquartile range: 20.4-35.7). 96% of patients were still being treated with lanadelumab at the end of data collection. When looking at dose intervals, it is noticeable that 6 months after starting lanadelumab LTP, 30% of patients had already switched to an interval >2 weeks. 9.1% had an interval of four weeks and 8.1% had one of 3 weeks; 12.2% switched to a different interval. As the study progressed, the q2w dose interval was extended in an increasing number of patients (Fig. 1) . 36 months after Baselinec, the proportion of those with a 2-week interval was only 26.7%. “The others had longer intervals – most of them four weeks, some three weeks, eight weeks or other intervals,” the speaker said.

b Germany n=76, France n=86, Austria n=14, Greece n=22
c before initiation of lanadelumab LTP.

Conclusion: Lanadelumab improved seizure freedom

Primary endpoints included the efficacy of lanadelumab on cumulative and monthly seizure-free rate (AFR) and the effect of increasing the dose interval (q2w) on AFR. The final analysis suggests that lanadelumab LTP significantly improves AFR. Monthly AFRs ranged from 16.2% to 28.3% during the pre-index event period and from 82.7% to 84.8% thereafter (months 1 and 2), reaching as high as >95% (months 26, 36, 38, 39, and 41+). None of the patients had life-threatening seizures after the index event.

d Index event = onset of lanadelumab LTP.

Source: “Real-world Effectiveness of Lanadelumab in European Patients with HAE Type I/II: Results from the Retrospective INTEGRATED Study,” Prof. Markus Magerl, MD, Flash Talks 000786. EEACI Annual Meeting, 9–11 June 2023.

DERMATOLOGIE PRAXIS 2023; 33(4): 25

Cover image: LucyHAE, wikimedia
Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • DERMATOLOGIE PRAXIS
Related Topics
  • Berotralstat
  • Dose interval
  • hereditary angioedema
  • INTEGRATED Study
  • Lanadelumab
  • Long-term prophylaxis
  • Real-World Data
Previous Article
  • Chronic rhinosinusitis

Endotyping as a basis for targeted treatment

  • Allergology and clinical immunology
  • Congress Reports
  • General Internal Medicine
  • ORL
  • RX
  • Studies
View Post
Next Article
  • Pulmonary arterial hypertension (PAH)

Results of the Phase III STELLAR study show therapeutic progress

  • Cardiology
  • Congress Reports
  • Pneumology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.